Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | BCHE | P06276 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15472846 | 0.92 | SMN1; SMN2 (0.54) | SMN1; SMN2TP53ALDH1A1MAPTBCHE | |
| SCHEMBL13449689 | 0.92 | ALDH1A1 (0.56) | SMN1; SMN2TP53ALDH1A1HSD17B10KDM4E | |
| SCHEMBL11890508 | 0.91 | SMN1; SMN2 (0.58) | SMN1; SMN2TP53ALDH1A1MAPTBCHE | |
| SCHEMBL2582550 | 0.90 | ALDH1A1 (0.64) | SMN1; SMN2TP53ALDH1A1HSD17B10KDM4E | |
| SCHEMBL15441092 | 0.90 | ALDH1A1 (0.53) | SMN1; SMN2TP53ALDH1A1HSD17B10KDM4E | |
| Avanbulin SCHEMBL1160317 | 0.88 | KDM4E (0.56) | SMN1; SMN2TP53ALDH1A1HSD17B10KDM4E | |
| SCHEMBL11301075 | 0.88 | ALDH1A1 (0.56) | SMN1; SMN2TP53ALDH1A1HSD17B10KDM4E | |
| Avanbulin SCHEMBL29374555 | 0.88 | KDM4E (0.56) | SMN1; SMN2TP53ALDH1A1HSD17B10KDM4E | |
| SCHEMBL13449702 | 0.88 | ALDH1A1 (0.53) | SMN1; SMN2TP53ALDH1A1HSD17B10KDM4E | |
| SCHEMBL13449688 | 0.88 | ALDH1A1 (0.55) | SMN1; SMN2TP53ALDH1A1HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11419856-B2 | Pharmaceutical combinations for use in the treatment of neoplastic diseases | Basilea Pharmaceutica International AG (CH) | 2022-08-23 | — | — | US | disclosed |
| US-20220031670-A1 | PHARMACEUTICAL COMBINATIONS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | BASILEA PHARM INT AG (CH) | 2022-02-03 | — | — | US | disclosed |
| WO-2021048135-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A FURAZANOBENZIMIDAZOLES AND A CD40 AGONIST FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | Basilea Pharmaceutica International AG (CH) | 2021-03-18 | — | — | WO | disclosed |
| US-20200390749-A1 | PHARMACEUTICAL COMBINATIONS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | BASILEA PHARM INT AG (CH) | 2020-12-17 | — | — | US | disclosed |
| US-20200237730-A1 | NOVEL DOSAGE PRINCIPLE FOR DRUGS USEFUL FOR TREATING NEOPLASTIC DISEASES | Basilea Pharmaceutica International AG (CH) | 2020-07-30 | — | — | US | disclosed |
| US-10724072-B2 | Use of phospho-Akt as a biomarker of drug response | BASILEA PHARMACEUTICA AG (CH) | 2020-07-28 | — | — | US | disclosed |
| US-10656162-B2 | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2020-05-19 | — | — | US | disclosed |
| US-10222377-B2 | Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2019-03-05 | — | — | US | disclosed |
| US-9995754-B2 | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2018-06-12 | — | — | US | disclosed |
| US-9995754-B2 | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2018-06-12 | — | — | US | disclosed |
| US-9366682-B2 | Use of stathmin as a biomarker of drug response to furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2016-06-14 | — | — | US | disclosed |
| EP-2459553-B1 | FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES | BASILEA PHARMACEUTICA AG (CH) | 2014-10-01 | — | — | EP | disclosed |
| US-8802858-B2 | Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases | BASILEA PHARMACEUTICA AG (CH) | 2014-08-12 | — | — | US | disclosed |
| US-8802858-B2 | Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases | BASILEA PHARMACEUTICA AG (CH) | 2014-08-12 | — | — | US | disclosed |
| US-20140080872-A1 | USE OF PHOSPHO-AKT AS A BIOMARKER OF DRUG RESPONSE | BASILEA PHARMACEUTICA AG (CH) | 2014-03-20 | — | — | US | disclosed |
| US-20140045897-A1 | USE OF BUBR1 AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140024686-A1 | USE OF GLU-TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2014-01-23 | — | — | US | disclosed |
| US-20140024686-A1 | USE OF GLU-TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2014-01-23 | — | — | US | disclosed |
| US-20120264792-A1 | FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES | BASILEA PHARMACEUTICA AG | 2012-10-18 | — | — | US | disclosed |
| US-20120264792-A1 | FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES | BASILEA PHARMACEUTICA AG | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10724072-B2 | Use of phospho-Akt as a biomarker of drug response | AKT3, AKT1S1, AKT2 | SMN1; SMN2 3340/4885TP53 60/4885ALDH1A1 4829/4885 |
| US-20120264792-A1 | FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES | SSB, VHL, AHR | SMN1; SMN2 2944/4885TP53 303/4885ALDH1A1 838/4885 |
| US-10656162-B2 | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles | TUBB, TUBB1, TUBB6 | SMN1; SMN2 3419/4885TP53 261/4885ALDH1A1 1153/4885 |
| US-20140024686-A1 | USE OF GLU-TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | TUBB, TUBB1, TUBB6 | SMN1; SMN2 3419/4885TP53 261/4885ALDH1A1 1153/4885 |
| US-20140045897-A1 | USE OF BUBR1 AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BUB1B, BUB1, BUB3 | SMN1; SMN2 4014/4885TP53 46/4885ALDH1A1 1640/4885 |
| US-20200390749-A1 | PHARMACEUTICAL COMBINATIONS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | ERLIN1, EDNRB, ERLIN2 | SMN1; SMN2 2238/4885TP53 44/4885ALDH1A1 838/4885 |
| US-11419856-B2 | Pharmaceutical combinations for use in the treatment of neoplastic diseases | ERLIN1, EDNRB, ERLIN2 | SMN1; SMN2 2238/4885TP53 44/4885ALDH1A1 838/4885 |
| US-10222377-B2 | Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles | BUB1B, BUB1, BUB3 | SMN1; SMN2 4014/4885TP53 46/4885ALDH1A1 1640/4885 |
| US-20200237730-A1 | NOVEL DOSAGE PRINCIPLE FOR DRUGS USEFUL FOR TREATING NEOPLASTIC DISEASES | SLC10A1, SLC10A2, SLC5A11 | SMN1; SMN2 667/4885TP53 604/4885ALDH1A1 846/4885 |
| US-20220031670-A1 | PHARMACEUTICAL COMBINATIONS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | KRAS, GLS, SLC28A1 | SMN1; SMN2 522/4885TP53 39/4885ALDH1A1 358/4885 |
| US-20140080872-A1 | USE OF PHOSPHO-AKT AS A BIOMARKER OF DRUG RESPONSE | AKT3, AKT1S1, AKT2 | SMN1; SMN2 4341/4885TP53 171/4885ALDH1A1 4641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.